Ningetinib

• Description:

  Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and c-Met, VEGFR2 and Axl, respectively.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  C-Met/HGFR; TAM Receptor; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Ningetinib.html

• Purity:

  99.82

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CC1=C(C(NC2=CC(F)=C(OC3=CC=NC4=C3C=CC(OCC(C)(O)C)=C4)C=C2)=O)C(N(C5=CC=CC=C5)N1C)=O

• Molecular Formula:

  C31H29FN4O5

• Molecular Weight:

  556.58

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74 (19 Suppl) :Abstract nr 1755.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  Axl; VEGFR2/KDR/Flk-1

• CAS Number:

  [1394820-69-9]